|
1
|
Loblaw DA, Virgo KS, Nam R, Somerfield MR,
Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott
J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL and Scher HI;
American Society of Clinical Oncology. Initial hormonal management
of androgen-sensitive metastatic, recurrent, or progressive
prostate cancer: 2006 update of an American Society of Clinical
Oncology practice guideline. J Clin Oncol. 25:1596–1605. 2007.
View Article : Google Scholar
|
|
2
|
Devlin HL and Mudryj M: Progression of
prostate cancer: multiple pathways to androgen independence. Cancer
Lett. 274:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
So A, Gleave M, Hurtado-Col A and Nelson
C: Mechanisms of the development of androgen independence in
prostate cancer. World J Urol. 23:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schröder FH: Progress in understanding
androgen-independent prostate cancer (AIPC): a review of potential
endocrine-mediated mechanisms. Eur Urol. 53:1129–1137. 2008.
|
|
5
|
Chi KN, Bjartell A, Dearnaley D, Saad F,
Schröder FH, Sternberg C, Tombal B and Visakorpi T:
Castration-resistant prostate cancer: from new pathophysiology to
new treatment targets. Eur Urol. 56:594–605. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pilat MJ, Kamradt JM and Pienta KJ:
Hormone resistance in prostate cancer. Cancer Metastasis Rev.
17:373–381. 1999. View Article : Google Scholar
|
|
7
|
Stein MN, Goodin S and Dipaola RS:
Abiraterone in prostate cancer: a new angle to an old problem. Clin
Cancer Res. 18:1848–1854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seruga B and Tannock IF:
Chemotherapy-based treatment for castration-resistant prostate
cancer. J Clin Oncol. 29:3686–3694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farnier M and Davignon J: Current and
future treatment of hyperlipidemia: the role of statins. Am J
Cardiol. 82:3J–10J. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Malhotra HS and Goa KL: Atorvastatin: an
updated review of its pharmacological properties and use in
dyslipidaemia. Drugs. 61:1835–1881. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacobs EJ, Rodriguez C, Bain EB, Wang Y,
Thun MJ and Calle EE: Cholesterol-lowering drugs and advanced
prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol
Biomarkers Prev. 16:2213–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Flick ED, Habel LA, Chan KA, et al: Statin
use and risk of prostate cancer in the California Men’s Health
Study cohort. Cancer Epidemiol Biomarkers Prev. 16:2218–2225.
2007.
|
|
13
|
Hamilton RJ, Banez LL, Aronson WJ, Terris
MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL and Freedland SJ:
Statin medication use and the risk of biochemical recurrence after
radical prostatectomy: results from the Shared Equal Access
Regional Cancer Hospital (SEARCH) Database. Cancer. 116:3389–3398.
2010. View Article : Google Scholar
|
|
14
|
Abedinpour P, Baron VT, Welsh J and
Borgström P: Regression of prostate tumors upon combination of
hormone ablation therapy and celecoxib in vivo. Prostate.
71:813–823. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dandekar DS, Lopez M, Carey RI and
Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments
chemotherapeutic drug-induced apoptosis by enhancing activation of
caspase-3 and -9 in prostate cancer cells. Int J Cancer.
115:484–492. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harris RE: Cyclooxygenase-2 (cox-2)
blockade in the chemoprevention of cancers of the colon, breast,
prostate, and lung. Inflammopharmacology. 17:55–67. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reddy BS, Wang CX, Kong AN, Khor TO, Zheng
X, Steele VE, Kopelovich L and Rao CV: Prevention of
azoxymethane-induced colon cancer by combination of low doses of
atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res.
66:4542–4546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y,
Shih WJ, Huang MT, Liu Y, Rabson A, Reddy B, Yang CS and Conney AH:
Atorvastatin and celecoxib in combination inhibits the progression
of androgen-dependent LNCaP xenograft prostate tumors to androgen
independence. Cancer Prev Res. 3:114–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng X, Cui XX, Avila GE, Huang MT, Liu
Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS
and Conney AH: Atorvastatin and celecoxib inhibit prostate PC-3
tumors in immunodeficient mice. Clin Cancer Res. 13:5480–5487.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hammacher A, Thompson EW and Williams ED:
Interleukin-6 is a potent inducer of S100P, which is up-regulated
in androgen-refractory and metastatic prostate cancer. Int J
Biochem Cell Biol. 37:442–450. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen T, Wang LH and Farrar WL: Interleukin
6 activates androgen receptor-mediated gene expression through a
signal transducer and activator of transcription 3-dependent
pathway in LNCaP prostate cancer cells. Cancer Res. 60:2132–2135.
2000.
|
|
22
|
Kim O, Jiang T, Xie Y, Guo Z, Chen H and
Qiu Y: Synergism of cytoplasmic kinases in IL6-induced
ligand-independent activation of androgen receptor in prostate
cancer cells. Oncogene. 23:1838–1844. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gazi MH, Gong A, Donkena KV and Young CY:
Sodium selenite inhibits interleukin-6-mediated androgen receptor
activation in prostate cancer cells via upregulation of
c-Jun. Clin Chim Acta. 380:145–150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smith PC, Hobisch A, Lin DL, Culig Z and
Keller ET: Interleukin-6 and prostate cancer progression. Cytokine
Growth Factor Rev. 12:33–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malinowska K, Neuwirt H, Cavarretta IT,
Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A and
Culig Z: Interleukin-6 stimulation of growth of prostate cancer in
vitro and in vivo through activation of the androgen receptor.
Endocr Relat Cancer. 16:155–169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee SO, Lou W, Johnson CS, Trump DL and
Gao AC: Interleukin-6 protects LNCaP cells from apoptosis induced
by androgen deprivation through the Stat3 pathway. Prostate.
60:178–186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei X, Du ZY, Cui XX, Verano M, Mo RQ,
Tang ZK, Conney AH, Zheng X and Zhang K: Effects of cyclohexanone
analogues of curcumin on growth, apoptosis and NF-κB activity in
PC-3 human prostate cancer cells. Oncol Lett. 4:279–284. 2012.
|
|
28
|
Zheng X, Chang RL, Cui XX, Avila GE,
Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN and
Conney AH: Effects of 12-O-tetradecanoylphorbol-13-acetate
(TPA) in combination with paclitaxel (Taxol) on prostate Cancer
LNCaP cells cultured in vitro or grown as xenograft tumors in
immunodeficient mice. Clin Cancer Res. 12:3444–3451. 2006.
|
|
29
|
Zheng X, Cui XX, Huang MT, Liu Y, Wagner
GC, Lin Y, Shih WJ, Lee MJ, Yang CS and Conney AH: Inhibition of
progression of androgen-dependent prostate LNCaP tumors to androgen
independence in SCID mice by oral caffeine and voluntary exercise.
Nutr Cancer. 64:1029–1037. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsu JC: Comparisons: Theory and Methods.
Chapman and Hall; New York, NY: 1996, View Article : Google Scholar
|
|
31
|
Zhao L, Wientjes MG and Au JL: Evaluation
of combination chemotherapy: integration of nonlinear regression,
curve shift, isobologram, and combination index analyses. Clin
Cancer Res. 10:7994–8004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirano T: The biology of interleukin-6.
Chem Immunol. 51:153–180. 1992. View Article : Google Scholar
|
|
33
|
Michalaki V, Syrigos K, Charles P and
Waxman J: Serum levels of IL-6 and TNF-α correlate with
clinicopathological features and patient survival in patients with
prostate cancer. Br J Cancer. 90:2312–2316. 2004.
|
|
34
|
Nakashima J, Tachibana M, Horiguchi Y, Oya
M, Ohigashi T, Asakura H and Murai M: Serum interleukin 6 as a
prognostic factor in patients with prostate cancer. Clin Cancer
Res. 6:2702–2706. 2000.PubMed/NCBI
|
|
35
|
Altieri DC: Targeting survivin in cancer.
Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shariat SF, Lotan Y, Saboorian H, Khoddami
SM, Roehrborn CG, Slawin KM and Ashfaq R: Survivin expression is
associated with features of biologically aggressive prostate
carcinoma. Cancer. 100:751–757. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Costantino L and Barlocco D: STAT 3 as a
target for cancer drug discovery. Curr Med Chem. 15:834–843. 2008.
View Article : Google Scholar : PubMed/NCBI
|
